Check patentability & draft patents in minutes with Patsnap Eureka AI!

Modified nucleoside phosphoramidites

A technology of oligonucleotides and nucleobases, applied in the field of modified nucleoside phosphoramidites

Pending Publication Date: 2020-07-28
JANSSSEN BIOPHARMA INC
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While synthetic methods exist for constructing modified oligonucleotides, additional synthetic options are required to synthesize a wide variety of modified oligonucleotides

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified nucleoside phosphoramidites
  • Modified nucleoside phosphoramidites
  • Modified nucleoside phosphoramidites

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-4

[0072]

[0073] Following the chemical transformations shown in Schemes 1, 2, 3, 4 and 5, appropriately protected 2'-O-methoxyethyl-3'-aminonucleoside-5'-phosphoramidite building blocks were prepared (executed Examples 1, 2, 3 and 4).

[0074] plan 1

[0075]

[0076] Scheme 1 discloses the synthesis of the uracil base 3'-NH-MMTr-2'-O-methoxyethylphosphoramidite (such as Example 1). The key 3'-azido-2'-methoxyethyl intermediate 3-3 was obtained in low yield via anhydrous intermediate 3-2.

[0077] Due to the low-yield alkylation, 3-1 was reacted with BOMCl / DBU to give the N-3 protected intermediate 3-4, which was obtained by using 2-bromoethyl methyl ether / Ag 2 O / NaI / DMF alkylation to give 2'-O-methoxyethyl derivatives 3-5. Using hydrogenation conditions (Pd / C / H 2 ) deprotection of the N-3-BOM group resulted in 10%-20% of the desired 3'-amino intermediate 3-6a, along with a significantly overreduced by-product 3-6b.

[0078] Scenario 2

[0079]

[...

Embodiment 2

[0091]

[0092] 2'-O-Methoxyethoxy-NH-benzoyl-cytosine phosphoramidite compound 5-4 obtained by conversion of uridine intermediate 4-8 to the 3'-aminocytidine analog 5-1 , followed by phosphorylation using known procedures to give the desired 2'-O-methoxyethoxycytidine phosphoramidite monomer 5-4, as shown in Scheme 3 below.

[0093] Option 3

[0094]

[0095] Preparation of intermediate (5-1) : To a solution of 4-8 (18.50 g, 27.30 mmol) in acetonitrile (250.00 mL) was added TPSCl (16.49 g, 54.60 mmol) and DMAP (6.67 g, 54.60 mmol), then TEA (5.52 g, 54.60 mmol) was added to the solution mmol, 7.56 mL). The reaction mixture was heated under N 2 Stir at room temperature for 5h. Will NH 4 OH (50.00 mL) was added to the reaction mixture. The mixture was stirred at room temperature for 12h. The solution was concentrated and extracted with EA. The organic layer was washed with brine, and washed with Na 2 SO 4 dry. The organic layer was concentrated and purified ...

Embodiment 3

[0100]

[0101] Synthesis of 2'-O-methoxyethyladenosine analogs 6-10 was achieved as shown in Scheme 4 below. Intermediate 6-2 under alkaline conditions (NH 3 / MeOH) afforded diol 6-3, which, after protection of the 5'-hydroxyl group using TBDPSCl, gave 6-4. (Intermediate 6-4.) Then, 6-42'-O was alkylated using 2-bromoethylmethyl ether / NaH / DMF to give the 2'-O-methoxyethyl derivative 6 -5, without the protection of the C-6-exocyclic amine of 6-4. The inventive method of selective alkylation of 2'-OH group of intermediate 6-4 was realized.

[0102] Option 4

[0103]

[0104] Reduction of the 3'-azido group of intermediate 6-5 to amine 6-7, which is then immediately protected, such as with 4-monomethoxytriphenylchloromethane to react with TBAF / THF on the 5' Deprotection of the -OTBDPS group gives precursors 6-8. Phosphorylation of 6-9 was performed using known procedures to give the desired 2'-O-methoxyethoxyadenine-NH-benzoylphosphoramidite monomers 6-10....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates to compounds and compositions containing 5'-phosphoramidite nucleoside monomers of formulae (I) and (II), and methods of making and use, wherein the substituents are asdefined in the appended claims.

Description

[0001] Cross References to Related Applications [0002] This application is a US application claiming the benefit of priority to US Provisional Application 62 / 558,763, filed September 14, 2017, which is hereby incorporated by reference in its entirety. Background technique [0003] Oligonucleotide synthesis is extremely important in providing access to custom-made oligonucleotides of desired sequence. To obtain the desired oligonucleotide, the building blocks (monomers) are sequentially coupled to the growing oligonucleotide chain in the order desired for the product sequence. [0004] Modified oligonucleotides with modifications, e.g. at the 2' and / or 3' positions, have received increasing attention over the past few years, as may be useful, e.g., in therapeutic applications. While synthetic methods exist for constructing modified oligonucleotides, additional synthetic options are required to synthesize a wide variety of modified oligonucleotides. In order to me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07H1/00C07H19/067C07H19/16C07H19/167C07H19/24C07H21/00C07H19/06
CPCC07H1/00C07H19/06C07H19/067C07H19/16C07H19/167C07H19/24C07H21/00Y02P20/55C07H19/23C07H19/10C07H19/20
Inventor S.格里亚佐夫J.洪V.K.拉万施
Owner JANSSSEN BIOPHARMA INC
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More